Skip to main content
OpenTrials
Completed

NCT Number: NCT02972905

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kinase (PI3K) delta inhibitor being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airway diseases, such as chronic obstructive pulmonary disease (COPD). The purpose of the study is to assess the safety, tolerability and pharmacokinetics (PK) of single and repeat doses of GSK2269557 administered via the ELLIPTA dry powder inhaler (DPI) to healthy Japanese subjects. This is the first time for Japanese subjects that GSK2269557 will be administered via the ELLIPTA DPI with the addition of magnesium stearate.

In each group of this study, subjects will receive a single dose of either GSK2269557 or placebo in Session 1 and receive daily dose of GSK2269557 or placebo for 10 days in Session 2. Session 1 of the next dose strength may be run in parallel with the Session 2 of the previous dose. The doses planned for the study are 200 micrograms (mcg), 500 mcg and 700 mcg. There will be at least 10 days washout between the two dosing sessions. Follow up period will start 10 days (+-1 day) after the last dose of Session 2. A total number of 36 subjects will be enrolled for the study with 27 subjects receiving a dose strength of GSK2269557 and 9 subjects will receive each dose strength of GSK2269557. ELLIPTA is a trademark of the GSK group of companies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

20 year–64 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site

Fukuoka, 813-0017, Japan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be 20 to 64 years of age inclusive, at the time of signing the informed consent.
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Normal spirometry (forced expiratory volume in 1 second >=80% of predicted) at Screening.
  • Body weight >=50 kilograms (kg) and body mass index (BMI) within the range 18.5 to 24.9 kg/square meter (m^2) (inclusive).
  • Japanese Male: A male participant must agree to use contraception of this protocol during the treatment period and until follow up visit.
  • Capable of giving signed informed consent as described in restrictions listed in the informed consent form (ICF).

Exclusion criteria

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data
  • Abnormal blood pressure as determined by the investigator
  • ALT >1.5x upper limit of normal (ULN)
  • Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • QTcF >450 milliseconds (msec).
  • Past or intended use of over-the-counter or prescription medication including herbal medications within 14 days prior to dosing.
  • History of donation of blood or blood products >=400 milliliters (mL) within 3 months or >=200 mL within 1 month prior to screening
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day
  • Current enrollment or past participation within the last 30 days before signing of consent in this clinical study involving an investigational study treatment or any other type of medical research
  • The subject is positive Serological test for syphilis (rapid plasma reagin and Treponema pallidum), Human immunodeficiency virus (HIV) Antigen/Antibody, Hepatitis B surface antigen (HbsAg), Hepatitis C virus (HCV) antibody, or Human T-cell lymphotropic virus type 1 (HTLV-1) antibody at screening.
  • Positive pre-study drug screen
  • Regular use of known drugs of abuse
  • Regular alcohol consumption within 6 months prior to the study defined as: for an average weekly intake of >14 units for males. One unit is equivalent to 350 ml of beer, 150 ml of wine or 45 ml of 80 proof distilled spirits
  • Smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening
  • Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study

Treatment and study plan

GSK2269557 ELLIPTA DPI

Drug

GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Placebo ELLIPTA DPI

Drug

Placebo ELLIPTA DPI contains lactose

Primary outcomes

  1. Number of subjects with any adverse event(s) (AE) and serious adverse event(s) (SAE)

    Time frame: Approximately up to 37 days

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.

  2. Session 1: Number of subjects having abnormal clinical laboratory parameters as a measure of safety

    Time frame: Approximately up to 4 days

    Blood samples will be collected to analyse blood urea nitrogen, creatinine, glucose (fasting), uric acid, high density lipoprotein-cholesterol, amylase, potassium, sodium, calcium, triglycerides, lactate dehydrogenase (LDH), chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total cholesterol, gamma-glutamyl transpeptidase (GGT), phosphorus, total bilirubin, direct bilirubin, total protein, albumin, low density lipoprotein-cholesterol, creatine phosphokinase (CPK)

  3. Session 2: Number of subjects having abnormal clinical laboratory parameters as a measure of safety

    Time frame: Approximately up to 22 days

    Blood samples will be collected to analyse blood urea nitrogen, creatinine, glucose (fasting), uric acid, high density lipoprotein-cholesterol, amylase, potassium, sodium, calcium, triglycerides, LDH, chloride, AST, ALT, ALP, total cholesterol, GGT, phosphorus, total bilirubin, direct bilirubin, total protein, albumin, low density lipoprotein-cholesterol, CPK

  4. Session 1:Number of subjects having abnormal hematology laboratory parameters as a measure of safety

    Time frame: Approximately up to 4 days

    Blood samples will be collected to analyse platelet count, Red Blood Cells (RBC) count, hemoglobin, hematocrit, RBC Indices, mean corpuscular volume ( MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes, White Blood Cells (WBC), neutrophils, lymphocytes, monocytes, eosionophils, and basophils

  5. Session 2: Number of subjects having abnormal hematology laboratory parameters as a measure of safety

    Time frame: Approximately up to 22 days

    Blood samples will be collected to analyse platelet count, RBC count, hemoglobin, hematocrit, RBC Indices, MCV, MCH, percent reticulocytes, WBC, neutrophils, lymphocytes, monocytes, eosionophils, and basophils

  6. Session 1: Number of subjects having abnormal urinalysis as a measure of safety

    Time frame: Approximately up to 4 days

    Urine samples will be collected to analyse specific gravity, pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen for dipstick, and microscopic examination

  7. Session 2: Number of subjects having abnormal urinalysis as a measure of safety

    Time frame: Approximately up to 22 days

    Urine samples will be collected to analyse specific gravity, pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen for dipstick, and microscopic examination

  8. Session 1: Body temperature assessment as a safety measure

    Time frame: Approximately up to 4 days

    Temperature will be recorded in a supine position after 5 minutes rest

  9. Session 2: Body temperature assessment as a safety measure

    Time frame: Approximately up to 22 days

    Temperature will be recorded in a supine position after 5 minutes rest

  10. Session 1: Blood pressure assessment as a safety measure

    Time frame: Approximately up to 4 days

    Systolic and diastolic blood pressure will be measured in a supine positon after 5 minutes rest

  11. Session 2: Blood pressure assessment as a safety measure

    Time frame: Approximately up to 22 days

    Systolic and diastolic blood pressure will be measured in a supine position after 5 minutes rest

  12. Session 1: Measurement of pulse rate as a safety measure

    Time frame: Approximately up to 4 days

    Pulse rate will be measured in a supine position after 5 minutes rest

  13. Session 2: Measurement of pulse rate as a safety measure

    Time frame: Approximately up to 22 days

    Pulse rate will be measured in a supine position after 5 minutes rest

  14. Session 1: Electrocardiogram (ECG) assessment as a measure of safety.

    Time frame: Approximately up to 4 days

    Single 12-lead ECG will be obtained in a supine position after 5 minutes rest using an ECG machine that measures PR, QRS, QT, and Corrected QT interval by Fridericia's formula (QTcF) intervals. Single ECGs will be obtained at each time point.

  15. Session 2: ECG assessment as a measure of safety.

    Time frame: Approximately up to 22 days

    Single 12-lead ECG will be obtained in a supine position after 5 minutes rest using an ECG machine that measures PR, QRS, QT, and QTcF intervals. Single ECGs will be obtained at each time point.

  16. Session 1: Spirometry assessment as a safety measure

    Time frame: Approximately up to 4 days

    Spirometry assessments will be performed whilst the subject is in a standing position. Assessments will be repeated until 3 technically acceptable measurements have been made.

  17. Session 2: Spirometry assessment as a safety measure

    Time frame: Approximately up to 22 days

    Spirometry assessments will be performed whilst the subject is in a standing position. Assessments will be repeated until 3 technically acceptable measurements have been made.

  18. Session 1: Area under the plasma concentration curve (AUC) from time zero to the time of last quantifiable concentration [AUC(0-t)]

    Time frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72hours (h) post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC [0-t]

  19. Session 1: AUC from time zero to 24 hours post dose [AUC(0-24)] of GSK2269557 following a single dose administration

    Time frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC[0-24]

  20. Session 1: AUC from time zero to infinity [AUC(0-infinity)] of GSK2269557 following a single dose administration

    Time frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC (0-infinity).

  21. Session 2: AUC from time zero to the time of last quantifiable concentration [AUC(0-t)] of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC [0-t]

  22. Session 2: AUC from time zero to 24 hours post dose [AUC(0-24)] of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC[0-24]

  23. Session 2: AUC from time zero to infinity [AUC(0-infinity)] of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating AUC (0-infinity)

  24. Session 1: Trough observed plasma drug concentration (Ctrough) of GSK2269557 following a single dose administration

    Time frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating Ctrough

  25. Session 1: Maximum observed plasma concentration (Cmax) of GSK2269557 following a single dose administration

    Time frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax

  26. Session 1: Maximum/trough observed plasma drug concentration (Cmax/Ctrough) of GSK2269557 following a single dose administration

    Time frame: Pre-dose, 5, 15, 30 minutes (min), 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax/Ctrough

  27. Session 2: Trough observed plasma drug concentration (Ctrough) of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating Ctrough

  28. Session 2: Maximum observed plasma concentration (Cmax) of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax

  29. Session 2: Maximum/trough observed plasma drug concentration (Cmax/Ctrough) of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating Cmax/Ctrough

  30. Session 1: Time to maximum observed plasma drug concentration (Tmax) of GSK2269557 following a single dose administration

    Time frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax

  31. Session 1: Terminal half-life (t1/2) of GSK2269557 following a single dose administration

    Time frame: Pre-dose, 5, 15, 30 min, 1, 2 , 4 , 6, 12, 24, 36, 48, and 72h post-dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating t1/2

  32. Session 2: Time to maximum observed plasma drug concentration (Tmax) of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax

  33. Session 2: Terminal half-life (t1/2) of GSK2269557 following repeat dose administration

    Time frame: Day 1: pre-dose, 5 min and 24 h post-dose; Day 2: 5 min post-dose; Days 3, 4, 5, 6, 7, 8, and 9: pre-dose and 5 min post-dose; Day 10: pre-dose, and 5 min, 30 min, 1 h, 2 h, 4 h, 6 h post-dose; 24 h, 48 h, 72 h, 96 h and 120 h post-Day 10 dose

    Blood samples will be collected at pre-dose and at specific post dose time points for calculating tmax and t1/2

  34. Ratio of accumulation factor (Ro) of GSK2269557 following single and repeat inhalations

    Time frame: Day 1 of session 2 and day 10 of session 2

    Ro is defined as AUC(0-24) of Session 2 at day10 divided by AUC(0-24) of Session1

  35. Ratio of accumulation factor (Rs) of GSK2269557 following single and repeat inhalations

    Time frame: Day 1 of session 2 and day 10 of session 2

    Rs is defined as AUC(0-24) of Session 2 at day10 divided by AUC(0-infinity) of Session 1

  36. Ratio of accumulation factor (R[Cmax]) of GSK2269557 following single and repeat inhalations

    Time frame: Day 1 of session 2 and day 10 of session 2

    R[Cmax] is defined as Cmax of Session 2 at day10 divided by Cmax of Session 1

  37. Ratio of accumulation factor (R[Ctrough]) of GSK2269557 following single and repeat inhalations

    Time frame: Day 1 of session 2 and day 10 of session 2

    R[Ctrough] is defined as Ctrough of Session 2 at day10 divided by C24 of Session 1

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Single Center, Double-blind, Randomized, Placebo-controlled, Parallel, Single and Repeat, Dose-ascending Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Japanese Subjects

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Nov 25, 2016
Registry last updated
Jan 18, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.